Elisrasib
Elisrasib is an orally active inhibitor for KRAS. Elisrasib inhibits the proliferation of KRASG12C mutant H358 and MIA-PA-CA-2 with an IC50 of 0.6 and 0.44 nM. Elisrasib exhibits good metabolic stability in hepatocytes, liver microsomes, plasma and whole blood in various species. D3S-001 exhibits good pharmacokinetic characteristics and antitumor efficacy in mice[1].
Product Specifications
CAS Number
[2914919-85-8]
Product Name Alternative
D3S-001
UNSPSC
12352005
Target
Ras
Type
Reference compound
Related Pathways
GPCR/G Protein; MAPK/ERK Pathway
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/d3s-001.html
Purity
98.50
Smiles
FC(F)(F)C(C(C)=CC(N)=C1F)=C1[C@@H]2CC3=NC(OC[C@@]45N(CCC5)C[C@@H](C4)F)=NC(N6C[C@@H](N(CC6)C(C(F)=C)=O)CC#N)=C3CO2
Molecular Formula
C32H35F6N7O3
Molecular Weight
679.66
References & Citations
[1]Xu Y, et al., Crystal form of pyrimidine heterocyclic compound and preparation method therefor. WO2023036282.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
Recombinant Escherichia coli O9:H4 UPF0208 membrane protein YfbV (yfbV)
Recombinant Escherichia coli O9:H4 UPF0208 membrane protein YfbV (yfbV)
Recombinant Escherichia coli O9:H4 UPF0208 membrane protein YfbV (yfbV)